BioNexus Gene Lab Corp Common stock (BGLC) Key Ratios
$1.45
As on 04-Sep-2026 16:00EDT
Market cap
$4 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 233.40 | -96.63 | -67.27 | -32.92 | -31.67 |
| EBIT | -- | -- | 50.73 | -176.43 | -189.49 |
| Net Profit | 47.30 | 53.51 | 12.21 | -237.09 | -206.61 |
| EPS | 47.30 | 65.45 | 28.54 | -325.14 | -189.76 |
| Book Value | -- | -- | -23.06 | 97.82 | -14.34 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -27.67 | -15.56 | -39.96 | -39.93 | -16.55 |
| Net Margin
| -- | 5.72 | -82.36 | -- | -- |
| Return on equity
| -28.41 | -15.90 | -31.42 | -35.24 | -17.78 |
| Return on Capital
| -27.90 | -15.62 | -- | -34.46 | -17.43 |
| Return on Assets
| -23.69 | -13.46 | -20.73 | -30.32 | -14.64 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.02 | 0.03 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
-34.46
|
-17.43
|
-31.82
|
-5.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-31.42
Lower than Peers by 39.38
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-31.42
|
-35.24
|
-17.78
|
-32.21
|
-5.14
|
|
Peer Median
|
7.96
|
--
|
--
|
--
|
--
|
ROA
-20.73
Lower than Peers by 22.87
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-20.73
|
-30.32
|
-14.64
|
-26.11
|
-3.89
|
|
Peer Median
|
2.14
|
--
|
--
|
--
|
--
|
EBIT Margin
-39.96
Lower than Peers by 47.02
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-39.96
|
-39.93
|
-16.55
|
-26.54
|
-2.66
|
|
Peer Median
|
7.06
|
--
|
--
|
--
|
--
|
Net Margin
-82.36
Lower than Peers by 85.52
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-82.36
|
-40.20
|
-16.81
|
-26.91
|
-3.26
|
|
Peer Median
|
3.16
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-67.27
Lower than Peers by 77.10
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-67.27
|
-0.22
|
-0.03
|
-0.11
|
-0.18
|
|
Peer Median
|
9.83
|
--
|
--
|
--
|
--
|
EBIT Growth
50.73
Higher than Peers by 34.52
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
50.73
|
-88.41
|
39.32
|
-790.72
|
-127.58
|
|
Peer Median
|
16.21
|
--
|
--
|
--
|
--
|
Net Profit Growth
12.21
Lower than Peers by 4.97
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
12.21
|
-86.73
|
39.20
|
-638.57
|
-147.36
|
|
Peer Median
|
17.18
|
--
|
--
|
--
|
--
|
EPS Growth
28.54
Higher than Peers by 12.44
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
28.54
|
-0.87
|
-3.86
|
0.54
|
-1.47
|
|
Peer Median
|
16.10
|
--
|
--
|
--
|
--
|
Book Value Growth
-23.14
Lower than Peers by 28.26
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-23.14
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.12
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
0.02
|
0.03
|
0.02
|
0.01
|
|
Peer Median
|
0.38
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
0.01
|
0.01
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.08
Higher than Peers by 4.60
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
6.08
|
10.46
|
3.81
|
4.93
|
3.00
|
|
Peer Median
|
1.48
|
--
|
--
|
--
|
--
|
Quick Ratio
5.28
Higher than Peers by 3.90
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
5.28
|
9.16
|
3.10
|
4.24
|
2.52
|
|
Peer Median
|
1.38
|
--
|
--
|
--
|
--
|
Interest Coverage
-199.57
Lower than Peers by 203.89
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
-199.57
|
-151.73
|
-74.42
|
-186.20
|
-23.33
|
|
Peer Median
|
4.32
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
5.94
Lower than Peers by 7.19
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
5.94
|
8.74
|
16.62
|
8.77
|
26.53
|
|
Peer Median
|
13.12
|
--
|
--
|
--
|
--
|
Asset Turnover
0.25
Lower than Peers by 0.52
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
0.25
|
0.75
|
0.87
|
0.97
|
1.19
|
|
Peer Median
|
0.78
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
54.83
|
46.81
|
70.22
|
104.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
59.50
|
56.12
|
45.77
|
47.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
43.37
|
64.54
|
70.60
|
73.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
70.95
|
38.38
|
45.40
|
78.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
-2.65
|
-0.35
|
-3.23
|
-2.67
|
|
Peer Median
|
33.81
|
--
|
--
|
--
|
--
|
Price / Book Value
0.55
Lower than Peers by 2.98
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
0.55
|
0.92
|
0.07
|
0.88
|
0.14
|
|
Peer Median
|
3.54
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
629.53
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
629.53
|
-1.44
|
4.51
|
0.24
|
14.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
4
Lower than Peers by 354
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
4
|
--
|
--
|
--
|
--
|
|
Peer Median
|
358
|
--
|
--
|
--
|
--
|